AbbVie's Rinvoq Wins EU Approval for Alopecia Areata and Vitiligo
The European Commission approved AbbVie's Rinvoq (upadacitinib) on July 29, 2026 for two additional autoimmune skin conditions, severe alopecia areata and non-segmental vitiligo, expanding the reach of a drug already used for several other immune-mediated diseases.
Non-segmental vitiligo is the more common form of vitiligo, a condition in which the immune system attacks the pigment-producing cells in the skin, causing patches of skin to lose their color, often in a roughly symmetrical pattern across the body. The new approval makes Rinvoq the first systemic, whole-body medicine authorized in the European Union specifically for this form of vitiligo, giving patients an oral option rather than relying solely on topical treatments or light therapy.
The vitiligo approval was supported by data from the Phase 3 Viti-Up clinical program. Patients taking Rinvoq showed statistically significant repigmentation compared with placebo by week 48, measured both across the total body and specifically on the face, an area that carries particular emotional weight for many patients because of its visibility.
On the same day, the European Commission also approved Rinvoq for adults and adolescents with severe alopecia areata, the autoimmune condition that causes patchy or complete hair loss. Rinvoq is a JAK inhibitor, a class of drugs that works by blocking specific signaling enzymes inside immune cells, dampening the inflammatory processes that drive conditions like these. It had already been approved in various markets for conditions including rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and Crohn's disease, so this extends an already broad label into two more skin-focused autoimmune indications.
For patients, having one systemic drug approved across multiple related autoimmune skin conditions can simplify care for people who may have more than one of these overlapping immune-mediated diseases, and it gives dermatologists another option beyond the handful of specialty treatments that have emerged in recent years. As with other JAK inhibitors, Rinvoq carries warnings in some markets around risks such as serious infections, blood clots, and certain cancers, and prescribers will need to weigh those risks against the benefit of repigmentation or hair regrowth on a patient by patient basis.
The approval described here is specific to the European Union; the medicine's regulatory status for these two indications may differ in the United States and other regions, where separate reviews and approval timelines apply. Patients outside the EU interested in these uses should talk to their doctor about what is currently approved and available where they live.